Amelioration of reductions of coenzyme Q.sub.10 in cardiomyopathy patients receiving lovastatin
US5082650A · kind A · utility
8Cited by
2References
1Claims
0Family size
Inventors
Key dates
| Filing date | Sep 7, 1989 |
| Grant date | Jan 21, 1992 |
| Priority date | — |
| Expiry date | Sep 7, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/365
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises the serious side effect of mevinolin to depress body levels of coenzyme Q.sub.10 and to correspondingly depress cardiac function and the circumvention of this side effect by the clinical administration of a formulation of coenzyme Q.sub.10 concommitantly with the administration of the mevinolin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.